我们的投资组合公司在这里提供帮助.
基金3公司
Inotrem has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses
Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP).
Calypso Biotech是一家免疫治疗生物技术公司, 从默克雪兰诺剥离出来, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs.
Ermium Therapeutics is a biotech company developing functionally selective immunomodulators targeting CXCR4 for auto-immune disease indications, 尤其是interferonopathies, 包括系统性红斑狼疮.
Priothera is developing an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.
Corteria Pharmaceuticals is a spin off biotech company from Sanofi developing first-in-class drugs for the treatment of distinct heart failure subpopulations.
Dualyx is a Belgium-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases.
基金2公司
Chrono developed a biologically timed transdermal drug delivery system with a behavioral support delivered via an app to help people manage hard-to-treat conditions. 他们的第一个应用是戒烟. 该公司于2019年停止运营.
使用专有的胶原蛋白技术, Innocoll is developing a portfolio of products to treat post-operative pain and prevent post-surgical adhesions. Innocoll was listed on NASDAQ as INNL prior to its acquisition by Gurnet Point in 2017
使用神经调节疗法, Neuromod正在帮助患有慢性和衰弱性耳鸣的人, 非正式的说法是“耳鸣”."
炎性小体产生信号，引起免疫细胞对抗感染. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals. Inflazome was sold to Roche Pharmaceuticals in 2020 for an upfront consideration of €380M and additional consideration in the form of milestone payments.
开发独特的神经激肽(NK)受体拮抗剂组合, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity.
Velicept正在开发solabegron, a highly differentiated B3 agonist for overactive bladder (OAB) and irritable bowel syndrome (IBS). 该公司于2020年停止运营.
KaNDy Therapeutics was a UK based clinical-stage company focused on developing NT-814, 一个first-in-class, 每天一次, 双机制神经激肽-1,3受体拮抗剂. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). KaNDy was sold to Bayer Pharmaceuticals in 2020 for $425M up front and additional consideration in the form of milestone payments.
医疗显微仪器.r.l. (MMI) is developing a novel robotic platform specifically designed for open microsurgery. The platform allows the surgeon to control two tiny articulated microinstruments that offer motion scaling and tremor elimination, 提高手术成功率和患者预后.
Syndesi Therapeutics was developing molecules that uniquely modulate the synaptic vesicle protein SV2A, 哪一个在突触传递中起核心作用. Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi was sold to Abbvie in 2022 for $130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones
Neurent Medical is developing a device to treat inflammatory diseases of the nasal cavities. The initial product offering reduces the primary symptoms of rhinitis, congestion and rhinorrhoea.
基金1公司
在脂质科学方面有丰富的经验, Amarin正在将Vascepa商业化, 一种预防和治疗心血管疾病的新疗法. Fountain已经退出了这项投资.
在2014年10月被Acorda Therapeutics以5.25亿美元现金收购之前, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments.
Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. 该公司于2016年3月被Spark Therapeutics收购.
拥有一系列独特的介入神经血管设备, Neuravi正在改善中风患者的临床结果. 约翰逊 & 强生于2017年3月收购了该公司.
Mainstay Medical (MSTY) is commercializing an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP).
以人体免疫系统为目标, Opsona developed drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, 实体器官移植与肿瘤学. 该公司于2019年停止运营.
旨在帮助接受血管手术的人, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure.
Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. 他们现在被称为ArraVasc有限公司，专注于外周血管产品. 这种投资是不活跃的.
利用口服小分子, Trino Therapeutics was focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD). 该公司于2017年停止运营.
有一个植入式输液泵, Palyon医疗中心治疗慢性疼痛, 中枢神经系统的痉挛和疾病. 该公司于2015年停止运营.